Literature DB >> 21761511

Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a "Top-Down" approach to intestinal fibrosis in mice.

Laura A Johnson1, Amy Luke, Kay Sauder, David S Moons, Jeffrey C Horowitz, Peter D R Higgins.   

Abstract

BACKGROUND: The natural history of Crohn's disease follows a path of progression from an inflammatory to a fibrostenosing disease, with most patients requiring surgical resection of fibrotic strictures. Potent antiinflammatory therapies reduce inflammation but do not appear to alter the natural history of intestinal fibrosis. The aim of this study was to determine the relationship between intestinal inflammation and fibrogenesis and the impact of a very early "top-down" interventional approach on fibrosis in vivo.
METHODS: In this study we removed the inflammatory stimulus from the Salmonella typhimurium mouse model of intestinal fibrosis by eradicating the S. typhimurium infection with levofloxacin at sequential timepoints during the infection. We evaluated the effect of this elimination of the inflammatory stimulus on the natural history of inflammation and fibrosis as determined by gross pathology, histopathology, mRNA expression, and protein expression.
RESULTS: Fibrogenesis is preceded by inflammation. Delayed eradication of the inflammatory stimulus by antibiotic treatment represses inflammation without preventing fibrosis. Early intervention significantly ameliorates but does not completely prevent subsequent fibrosis.
CONCLUSIONS: This study demonstrates that intestinal fibrosis develops despite removal of an inflammatory stimulus and elimination of inflammation. Early intervention ameliorates but does not abolish subsequent fibrosis, suggesting that fibrosis, once initiated, is self-propagating, suggesting that a very early top-down interventional approach may have the most impact on fibrostenosing disease.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21761511      PMCID: PMC3206985          DOI: 10.1002/ibd.21812

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  20 in total

Review 1.  Epidemiology and the natural course of inflammatory bowel disease.

Authors:  P G Andres; L S Friedman
Journal:  Gastroenterol Clin North Am       Date:  1999-06       Impact factor: 3.806

Review 2.  Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies.

Authors:  S Vermeire; G van Assche; P Rutgeerts
Journal:  Aliment Pharmacol Ther       Date:  2007-01-01       Impact factor: 8.171

Review 3.  Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease.

Authors:  S Brand
Journal:  Gut       Date:  2009-08       Impact factor: 23.059

4.  Chemically induced mouse models of intestinal inflammation.

Authors:  Stefan Wirtz; Clemens Neufert; Benno Weigmann; Markus F Neurath
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

5.  Annual cost of care for Crohn's disease: a payor perspective.

Authors:  B G Feagan; M G Vreeland; L R Larson; M V Bala
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

6.  Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.

Authors:  Gary R Lichtenstein; Allan Olson; Suzanne Travers; Robert H Diamond; Donny M Chen; Michelle L Pritchard; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Stephen B Hanauer; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2006-05       Impact factor: 10.864

Review 7.  Predictors of fibrostenotic Crohn's disease.

Authors:  Florian Rieder; Ian C Lawrance; Andre Leite; Miquel Sans
Journal:  Inflamm Bowel Dis       Date:  2011-02-09       Impact factor: 5.325

8.  Risk of early surgery for Crohn's disease: implications for early treatment strategies.

Authors:  Bruce E Sands; Joanne E Arsenault; Michael J Rosen; Mazen Alsahli; Laurence Bailen; Peter Banks; Steven Bensen; Athos Bousvaros; David Cave; Jeffrey S Cooley; Herbert L Cooper; Susan T Edwards; Richard J Farrell; Michael J Griffin; David W Hay; Alex John; Sheldon Lidofsky; Lori B Olans; Mark A Peppercorn; Richard I Rothstein; Michael A Roy; Michael J Saletta; Samir A Shah; Andrew S Warner; Jacqueline L Wolf; James Vecchio; Harland S Winter; John K Zawacki
Journal:  Am J Gastroenterol       Date:  2003-12       Impact factor: 10.864

9.  Long-term evolution of disease behavior of Crohn's disease.

Authors:  Jacques Cosnes; Stéphane Cattan; Antoine Blain; Laurent Beaugerie; Franck Carbonnel; Rolland Parc; Jean-Pierre Gendre
Journal:  Inflamm Bowel Dis       Date:  2002-07       Impact factor: 5.325

10.  Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis.

Authors:  Guntram A Grassl; Yanet Valdez; Kirk S B Bergstrom; Bruce A Vallance; B Brett Finlay
Journal:  Gastroenterology       Date:  2008-01-09       Impact factor: 22.682

View more
  41 in total

1.  Fibrocytes, inflammation, and fibrosis in Crohn's disease: another piece of the puzzle.

Authors:  D Sorrentino
Journal:  Dig Dis Sci       Date:  2014-04       Impact factor: 3.199

Review 2.  Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease.

Authors:  Florian Rieder; Sean Kessler; Miquel Sans; Claudio Fiocchi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-08-09       Impact factor: 4.052

Review 3.  Quality of care in Crohn's disease.

Authors:  Govind K Makharia
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

4.  2,4,6-trinitrobenzene sulfonic acid-induced chronic colitis with fibrosis and modulation of TGF-β1 signaling.

Authors:  Emilien Loeuillard; Julien Bertrand; Anni Herranen; Chloé Melchior; Charlène Guérin; Moïse Coëffier; Moutaz Aziz; Pierre Déchelotte; Guillaume Savoye; Rachel Marion-Letellier
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

5.  Intestinal organoids: a model of intestinal fibrosis for evaluating anti-fibrotic drugs.

Authors:  Eva S Rodansky; Laura A Johnson; Sha Huang; Jason R Spence; Peter D R Higgins
Journal:  Exp Mol Pathol       Date:  2015-03-28       Impact factor: 3.362

Review 6.  Mechanisms for the Resolution of Organ Fibrosis.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Physiology (Bethesda)       Date:  2019-01-01

7.  Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts.

Authors:  Laura A Johnson; Eva S Rodansky; Andrew J Haak; Scott D Larsen; Richard R Neubig; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

8.  Matrix stiffness corresponding to strictured bowel induces a fibrogenic response in human colonic fibroblasts.

Authors:  Laura A Johnson; Eva S Rodansky; Kay L Sauder; Jeffrey C Horowitz; Justin D Mih; Daniel J Tschumperlin; Peter D Higgins
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

9.  The orphan nuclear receptor ROR alpha and group 3 innate lymphoid cells drive fibrosis in a mouse model of Crohn's disease.

Authors:  Bernard C Lo; Matthew J Gold; Michael R Hughes; Frann Antignano; Yanet Valdez; Colby Zaph; Kenneth W Harder; Kelly M McNagny
Journal:  Sci Immunol       Date:  2016-09-02

10.  Toward Molecular Imaging of Intestinal Pathology.

Authors:  Mariane Le Fur; Iris Y Zhou; Onofrio Catalano; Peter Caravan
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.